Patent intelligence · US
US 2019337950
BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS
BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS
Patent details — US 2019337950
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 7, 2019
- Expiration
- Nov 2, 2039
- Applicant
- BIAL PORTELA & Cª S A [PT]
- CPC classes
- A61K/3140, A61K/314025, A61K/31403, A61K/314035
Quick answer
US 2019337950 (BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS) is held by BIAL PORTELA & Cª S A [PT]. Status: granted. Granted Nov 7, 2019. Expires Nov 2, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIAL PORTELA & Cª S A [PT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K/3140, A61K/314025, A61K/31403, A61K/314035, A61K/314178, A61K/314188
More from BIAL PORTELA & Cª S A [PT]
Related pharmaceutical patents in our USPTO index.
-
WO 2026106499
ANTAGONISTES DU RÉCEPTEUR DE L'ORÉXINE : COMPOSÉS 2-AZABICYCLIQUES
granted -
WO 2026015039
THÉRAPIE GÉNIQUE POUR LE TRAITEMENT DE L'ENCÉPHALOPATHIE ÉPILEPTIQUE ASSOCIÉE À LA SYNGAP1
granted -
WO 2025211975
AGONISTES DU RÉCEPTEUR DE L'OREXINE
granted -
WO 2025023852
ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE MORPHOLINE
granted -
WO 2025023851
ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE MORPHOLINE
granted -
WO 2024242579
RÉGIMES DE TRAITEMENT DE LA MALADIE DE PARKINSON IDIOPATHIQUE PRÉCOCE
granted -
AU 2023244944
PRODRUGS OF OPICAPONE
granted -
WO 2024039256
RÉGIMES THÉRAPEUTIQUES POUR LA MALADIE DE PARKINSON
granted
Frequently asked questions
What is US patent 2019337950?
US 2019337950 (BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS) is held by BIAL PORTELA & Cª S A [PT]. Status: granted. Granted Nov 7, 2019. Expires Nov 2, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2019337950?
BIAL PORTELA & Cª S A [PT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2019337950 expire?
Our index shows an expiration date of Nov 2, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.